Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables. 2021

Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

The gastrointestinal tract is a rare site for metastatic lung cancer. Programmed cell death-ligand 1 (PD-L1) expression in lung cancer is a biomarker for the response to anti-PD-1/PD-L1 therapy. We investigated clinicopathological features and PD-L1 expression in 25 gastrointestinal metastatic tumors from the lung and primary adenocarcinoma of the small bowel. The small bowel was the most common site (16/25; 64%) of gastrointestinal tract lung cancer metastasis. A total of 19 (76%) of the gastrointestinal metastasis showed PD-L1 expression in ≥5% of tumor cells, with 14 (56%) showing high expression levels (≥50%). In contrast, 21 (84%) expressed PD-L1 in ≥5% immune cells, including 4 (16%) showing a high expression levels (≥50%). The PD-L1 expression on tumor cells and immune cells in primary lung cancer and corresponding gastrointestinal metastasis was concordant in 13 (68%) and 11 (58%) of the 19 paired cases, respectively. Small-bowel metastasis of lung cancer was characterized by a higher incidence of perforation (31% vs. 0%), ulcerated mass (83% vs. 60%), and neoplastic PD-L1 expression (75% vs. 0%) compared to primary small-bowel adenocarcinoma. Gastrointestinal metastasis from lung cancer might be a potential target for immune checkpoint inhibitor therapy, given its high expression of PD-L1.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D005260 Female Females
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
June 2019, Cancer communications (London, England),
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
November 2022, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
April 2021, Annals of diagnostic pathology,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
February 2020, Pathology, research and practice,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
November 2016, Journal of thoracic disease,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
July 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
October 2017, Diagnostic pathology,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
March 2020, Oncology letters,
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
February 2022, Life (Basel, Switzerland),
Eri Ishikawa, and Masato Nakaguro, and Masanao Nakamura, and Takeshi Yamamura, and Tsunaki Sawada, and Yasuyuki Mizutani, and Keiko Maeda, and Kazuhiro Furukawa, and Yoshie Shimoyama, and Hiroki Kawashima, and Mitsuhiro Fujishiro
December 2022, Tissue & cell,
Copied contents to your clipboard!